Get the Stockscreener App
3.585
0.69%
-0.025
After Hours:
3.71
0.125
+3.49%
Turn Therapeutics Inc stock is traded at $3.585, with a volume of 5,700.
It is down -0.69% in the last 24 hours and down -15.25% over the past month.
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.
See More
Previous Close:
$3.61
Open:
$3.63
24h Volume:
5,700
Relative Volume:
0.08
Market Cap:
$105.56M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-3.11%
1M Performance:
-15.25%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$3.55
$3.7073
1-Week Range:
$3.55
$3.99
52-Week Range:
$2.5701
$26.50
Turn Therapeutics Inc Stock (TTRX) Company Profile
Name
Turn Therapeutics Inc
Sector
Industry
Phone
(818) 564-4011
Address
250 NORTH WESTLAKE BLVD., WESTLAKE VILLAGE
Compare TTRX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TTRX
Turn Therapeutics Inc
|
3.585 | 106.30M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Turn Therapeutics Inc Stock (TTRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-29-25 | Initiated | D. Boral Capital | Buy |
Turn Therapeutics Inc Stock (TTRX) Latest News
Turn Therapeutics to Present at Upcoming TD Cowen and Oppenheimer Healthcare Conferences - BioSpace
Turn Therapeutics Highlights GX-03 Progress at Investor Conferences - TipRanks
Turn Therapeutics Inc Announces Presentations at Healthcare Conferences - TradingView
Will Turn Therapeutics Turn The Corner In 2026? - RTTNews
Positive Signs As Multiple Insiders Buy Turn Therapeutics Stock - Yahoo Finance
Analyzing Turn Therapeutics (TTRX) & The Competition - Defense World
When Will Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Turn A Profit? - Yahoo Finance
Turn Therapeutics Advances GX-03 Eczema Trial, Opening a New Catalyst for Investors - TipRanks
Reviewing Turn Therapeutics (TTRX) and Its Peers - Defense World
Turn Therapeutics' (TTRX) Buy Rating Reiterated at D. Boral Capital - MarketBeat
Turn Therapeutics (TTRX) vs. Its Peers Head to Head Survey - Defense World
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Turn Therapeutics advances atopic dermatitis trial, expands pipeline By Investing.com - Investing.com Nigeria
Speculative Buy on Turn Therapeutics: Proprietary Platform, Capital-Efficient Growth, and 2026 Milestones as Key Upside Catalysts - TipRanks
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Turn Therapeutics advances atopic dermatitis trial, expands pipeline - Investing.com
Turn Therapeutics Issues Corporate, Pipeline and Financial Updates - TipRanks
Turn Therapeutics Inc Announces Corporate and Pipeline Updates for 2026 - TradingView — Track All Markets
Turn Therapeutics Announces Corporate and Pipeline Updates and 2026 Outlook Ahead of the 44 - Business Wire
Financial Review: Turn Therapeutics (TTRX) & Its Peers - Defense World
TTRX Forecast — Price Target — Prediction for 2027 - TradingView — Track All Markets
Turn Therapeutics Reaches US$132m Market Cap Benefiting Insider Stock Buying - Sahm
Will Stoke Therapeutics Inc. stock split again soonVolume Spike & Technical Buy Zone Confirmations - ulpravda.ru
Great week for Turn Therapeutics Inc. (NASDAQ:TTRX) insiders who have 59% stake and they haven’t stopped buying - Yahoo Finance
Turn Therapeutics adds McKinsey veteran to board amid M&A focus By Investing.com - Investing.com Nigeria
Los Angeles Daily NewsTurn Therapeutics Inc.Common Stock (Nasdaq:TTRX) Stock Quote - FinancialContent
Turn Therapeutics appoints Martin Dewhurst to its board of directors - marketscreener.com
Turn Therapeutics Appoints Martin Dewhurst to its Board of Directors - TradingView — Track All Markets
Turn Therapeutics appoints veteran executive to board - TipRanks
Turn Therapeutics adds McKinsey veteran to board amid M&A focus - Investing.com
Turn Therapeutics Inc. Appoints Martin Dewhurst to Board of Directors - TradingView — Track All Markets
Turn Therapeutics (TTRX) Stock Analysis Report | Financials & Insights - Benzinga
Ceapro (OTCMKTS:CRPOF) vs. Turn Therapeutics (NASDAQ:TTRX) Head to Head Review - Defense World
Turn Therapeutics (NASDAQ:TTRX) Upgraded at D Boral Capital - Defense World
Turn Therapeutics (NASDAQ:TTRX) Upgraded to "Strong-Buy" at D Boral Capital - MarketBeat
Turn Therapeutics (NASDAQ:TTRX) Now Covered by Analysts at D. Boral Capital - Defense World
TTRX Analyst Forecasts - Quiver Quantitative
Turn Therapeutics Inc. Common Stock (TTRX) Stock News & Articles - 24/7 Wall St.
D. Boral Capital initiates Turn Therapeutics stock with Buy rating By Investing.com - Investing.com Canada
What date does Turn Therapeutics Inc.'s (TTRX) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Death Cross: Is Beam Therapeutics Inc. stock a defensive play in 2025Exit Point & Safe Entry Zone Identification - moha.gov.vn
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Will Tempest Therapeutics Inc. stock beat EPS estimatesJuly 2025 Weekly Recap & Weekly High Potential Stock Alerts - bolumsonucanavari.com
Portfolio Shifts: Is Enliven Therapeutics Inc. stock near bottom after decline2025 Volatility Report & Daily Entry Point Trade Alerts - moha.gov.vn
Will Whitehawk Therapeutics Inc. stock recover faster than market2025 Earnings Surprises & Detailed Earnings Play Alerts - Улправда
Can Karyopharm Therapeutics Inc. stock resist sector downturnsJuly 2025 Market Mood & High Accuracy Trade Alerts - Улправда
Why MiNK Therapeutics Inc. stock attracts global investors2025 Market Trends & Short-Term High Return Ideas - Улправда
Is Foghorn Therapeutics Inc. stock resilient to inflation2025 Support & Resistance & Real-Time Chart Breakout Alerts - Улправда
Why Anika Therapeutics Inc. stock remains on watchlistsMarket Activity Report & Community Trade Idea Sharing - Улправда
Will Neumora Therapeutics Inc. stock benefit from AI adoptionOil Prices & Weekly Setup with High ROI Potential - Улправда
Loss Report: Can Xilio Therapeutics Inc. stock outperform in 2025 bull marketJuly 2025 EndofMonth & High Win Rate Trade Alerts - Улправда
Turn Therapeutics Inc Stock (TTRX) Financials Data
There is no financial data for Turn Therapeutics Inc (TTRX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):